Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial von de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, Lassen, Ulrik

Volltext

Application of Liquid Biopsies in Cancer Targeted Therapy von Sumanasuriya, S, Lambros, MB, Bono, JS

Volltext

From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs von Carden, CP, Banerji, U, Kaye, SB, Workman, P, Bono, JS

Volltext

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects von Ferraldeschi, R, Welti, J, Luo, J, Attard, G, de Bono, J S

Volltext

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study von Antonarakis, Emmanuel S, Piulats, Josep M, Gross-Goupil, Marine, Goh, Jeffrey, Ojamaa, Kristiina, Hoimes, Christopher J, Vaishampayan, Ulka, Berger, Ranaan, Sezer, Ahmet, Alanko, Tuomo, de Wit, Ronald, Li, Chunde, Omlin, Aurelius, Procopio, Giuseppe, Fukasawa, Satoshi, Tabata, Ken-Ichi, Park, Se Hoon, Feyerabend, Susan, Drake, Charles G, Wu, Haiyan, Qiu, Ping, Kim, Jeri, Poehlein, Christian, de Bono, Johann Sebastian

Volltext

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 von Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

Volltext

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer von Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, C S, Fletcher, A, Gerald, W L, Moller, H, Reuter, V, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S

Volltext

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) von Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., Dearnaley, D., Parker, C., de Bono, J. S.

Volltext

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer von Attard, Gerhardt, Belldegrun, Arie S., De Bono, Johann S.

Volltext

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease (vol 20, 1210, 2020) von Collins, DC, Sundar, R, Constantinidou, A, Dolling, D, Yap, TA, Popat, S, O'Brien, ME, Banerji, U, De Bono, JS, Lopez, JS, Tunariu, N, Minchom, A

Volltext

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance von Guo, C, Sharp, A, Gurel, B, Crespo, M, Figueiredo, I, Jain, S, Vogl, U, Rekowski, J, Rouhifard, M, Gallagher, L, Yuan, W, Carreira, S, Chandran, K, Paschalis, A, Colombo, I, Stathis, A, Bertan, C, Seed, G, Goodall, J, Raynaud, F, Ruddle, R, Swales, KE, Malia, J, Bogdan, D, Tiu, C, Caldwell, R, Aversa, C, Ferreira, A, Neeb, A, Tunariu, N, Westaby, D, Carmichael, J, Fenor de la Maza, MDLD, Yap, C, Matthews, R, Badham, H, Prout, T, Turner, A, Parmar, M, Tovey, H, Riisnaes, R, Flohr, P, Gil, J, Waugh, D, Decordova, S, Schlag, A, Calì, B, Alimonti, A, De Bono, JS

Volltext

Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease von Collins, DC, Sundar, R, Constantidinou, A, Dolling, D, Yap, TA, Popat, S, O'Brien, ME, Banerji, U, De Bono, JS, Lopez, JS, Tunariu, N, Minchom, A

Volltext

Prostate carcinogenesis: inflammatory storms von De Bono, JS, Guo, C, Gurel, B, De Marzo, AM, Sfanos, KS, Mani, RS, Gil, J, Drake, CG, Alimonti, A

Volltext

PCN315 - Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer von Degeling, K, Mehra, N, Koffijberg, H, de Bono, JS, IJzerman, MJ

Volltext

Physicians’ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer von Degeling, K, Mehra, N, Koffijberg, H, de Bono, JS, IJzerman, MJ

Volltext

Editorial Comment: Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer von Lott, Felipe

Volltext

The ErbB receptor family: a therapeutic target for cancer von de Bono, Johann S., Rowinsky, Eric K.

Volltext

Advanced prostate cancer with ATM Loss: PARP and ATR inhibitors von Neeb, A, Herranz, N, Arce-Gallego, S, Miranda, S, Buroni, L, Yuan, W, Athie, A, Casals, T, Carmichael, J, Rodrigues, DN, Gurel, B, Rescigno, P, Rekowski, J, Welti, J, Riisnaes, R, Gil, V, Ning, J, Wagner, V, Casanova-Salas, I, Cordoba, S, Castro, N, Fenor de la Maza, MD, Seed, G, Chandran, K, Ferreira, A, Figueiredo, I, Bertan, C, Bianchini, D, Aversa, C, Paschalis, A, Gonzalez, M, Morales-Barrera, R, Suarez, C, Carles, J, Swain, A, Sharp, A, Gil, J, Serra, V, Lord, C, Carreira, S, Mateo, J, De Bono, JS

Volltext

Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer von Fletcher, C, Sulpice, E, Combe, S, Shibakawa, A, Leach, D, Hamilton, MP, Chrysostomou, SL, Sharp, A, Welti, J, Yuan, W, Dart, D, Knight, E, Ning, J, Francis, JC, Kounatidou, EE, Gaughan, L, Swain, A, Lupold, SE, De Bono, JS, McGuire, SE, Gidrol, X, Bevan, C

Volltext

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101) von Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Buhl-Jensen, P., Molife, R., Brown, R., de Bono, J. S., Evans, T. R. J.

Volltext